1
|
Brick C, Atouf O, Ouadghiri S, Drissi Bourhanbour A, Bougar S, Yakhlef I, Essakalli M. HLA typing and haematopoietic stem cell transplantation in the histocompatibility unit of the Ibn Sina University Hospital in Rabat (Morocco). Transfus Clin Biol 2018; 26:293-298. [PMID: 30366818 DOI: 10.1016/j.tracli.2018.09.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2018] [Accepted: 09/27/2018] [Indexed: 11/17/2022]
Abstract
PURPOSE OF STUDY This study focuses on the search for a suitable related HLA-matched donor of haematopoietic stem cells in the context of allogeneic transplantation in Morocco. The aim of this work is to establish whether the related donor can meet graft needs in Moroccan patients. PATIENTS AND METHODS 429 families (429 recipients and 965 donors) benefited from HLA typing, using microlymphocytotoxicity, polymerase chain reaction-sequence specific primer and/or high-resolution polymerase chain reaction-specific sequence oligonucleotide. RESULTS The recipients and donors are mostly men over 18 years of age. In total, 86.8% of the recipients have between 1 and 3 donors who are 96% of the collaterals. Malignant haemopathies account for 54% of allograft indications. Benign haemopathies are more frequent than malignant in children, whereas the profile is reversed in adults. Fifty percent of recipients have an HLA identical donor in their siblings and 42% and HLA haplo identical donor. The HLA typing of the recipients and the donors reveals very large polymorphism of the population. CONCLUSION The related donor of haematopoietic stem cells represents an important source of grafts but will not be able to satisfy all the needs of Morocco. The creation of national unrelated voluntary donors will open up new possibilities for recipients who do not have a compatible donor within his relatives.
Collapse
Affiliation(s)
- C Brick
- Department of immunology and transfusion, CHU Ibn Sina Rabat, Rabat, Morocco.
| | - O Atouf
- Department of immunology and transfusion, CHU Ibn Sina Rabat, Rabat, Morocco; UPR of immunology, faculty of medicine and pharmacy, university Mohamed V Rabat, Rabat, Morocco
| | - S Ouadghiri
- Department of immunology and transfusion, CHU Ibn Sina Rabat, Rabat, Morocco
| | | | - S Bougar
- Department of immunology and transfusion, CHU Ibn Sina Rabat, Rabat, Morocco
| | - I Yakhlef
- Department of immunology and transfusion, CHU Ibn Sina Rabat, Rabat, Morocco; UPR of immunology, faculty of medicine and pharmacy, university Mohamed V Rabat, Rabat, Morocco
| | - M Essakalli
- Department of immunology and transfusion, CHU Ibn Sina Rabat, Rabat, Morocco; UPR of immunology, faculty of medicine and pharmacy, university Mohamed V Rabat, Rabat, Morocco
| |
Collapse
|
2
|
Barnoud D, Pinçon C, Bruno B, Béné J, Gautier S, Lahoche A, Petitpain N, Vasseur M, Barthélémy C, Décaudin B, Simon N, Odou P. Acute kidney injury after high dose etoposide phosphate: A retrospective study in children receiving an allogeneic hematopoetic stem cell transplantation. Pediatr Blood Cancer 2018. [PMID: 29528179 DOI: 10.1002/pbc.27038] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
BACKGROUND Etoposide phosphate (EP; single injection, 60 mg/kg) followed by total body irradiation (TBI) at 12 Gy has been used as an allogeneic stem cell transplantation (allo-SCT) conditioning regimen for children since 2010. In our institution, EP has been suspected of leading to acute nephrotoxicity. The aim of this study was to assess the potential renal toxicity of EP in this context. MATERIALS AND METHODS A retrospective study was carried out on children hospitalized between 2007 and 2015 for allo-SCT with TBI-based myeloablative conditioning associated with cyclophosphamide (CY, 60 mg/kg/day × 2 days) or EP. The primary endpoint of the study was the occurrence of acute kidney injury (AKI). Additional endpoints were time to recovery for children with AKI, survival, and treatment-related mortality. RESULTS Thirty-five patients were analyzed (CY: 22 vs. EP: 13). AKI occurred more frequently in the EP group than in the CY one (69% vs. 27%, adjusted odds ratio 6.0, 95% confidence interval [CI] [1.145; 31.445], P = 0.03). The median time to recovery was estimated at 3 days, 95% CI (2; 17), with CY and 11 days 95% CI (5; 18) with EP (adjusted hazard ratio of recovery for EP vs. CY 0.262, 95% CI [0.071; 0.969], P = 0.04). No significant difference was highlighted between the two treatments for survival or for treatment-related mortality. DISCUSSION This study shows that EP at high dosage or one of its excipients is probably responsible for AKI, as compared to CY. Further studies are required to explore the origin of this adverse effect.
Collapse
Affiliation(s)
| | - Claire Pinçon
- EA 2694-Santé publique: épidémiologie et qualité des soins, Université de Lille, Lille, France
| | - Bénédicte Bruno
- Service d'Hématologie Pédiatrique, Centre Hospitalier Regional Universitaire de Lille, Lille, France
| | - Johana Béné
- Centre Régional de Pharmacovigilance, Centre Hospitalier Regional Universitaire de Lille, Lille, France.,U1171-Degenerative & Vascular Cognitive Disorders, Université de Lille, Lille, France
| | - Sophie Gautier
- Centre Régional de Pharmacovigilance, Centre Hospitalier Regional Universitaire de Lille, Lille, France.,U1171-Degenerative & Vascular Cognitive Disorders, Université de Lille, Lille, France
| | - Annie Lahoche
- Service de Néphrologie Pédiatrique, Centre Hospitalier Regional Universitaire de Lille, Lille, France
| | - Nadine Petitpain
- Laboratoire de pharmacologie clinique et toxicologie, centre régional de pharmacovigilance de Lorraine, hôpital Central, Centre Hospitalier Regional Universitaire de Nancy, Nancy, France
| | - Michèle Vasseur
- CHU Lille, Institut de Pharmacie, F-59000, Lille, France.,Univ. Lille, EA 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées, F-59000, Lille, France
| | - Christine Barthélémy
- Univ. Lille, EA 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées, F-59000, Lille, France
| | - Bertrand Décaudin
- CHU Lille, Institut de Pharmacie, F-59000, Lille, France.,Univ. Lille, EA 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées, F-59000, Lille, France
| | - Nicolas Simon
- CHU Lille, Institut de Pharmacie, F-59000, Lille, France.,Univ. Lille, EA 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées, F-59000, Lille, France
| | - Pascal Odou
- CHU Lille, Institut de Pharmacie, F-59000, Lille, France.,Univ. Lille, EA 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées, F-59000, Lille, France
| |
Collapse
|